$XAIR

Beyond Air, Inc.

Beyond Air is a commercial-stage medical device and biopharmaceutical company headquartered in Garden City, New York. It develops nitric oxide generators and delivery systems under the LungFit® platform, which generates nitric oxide from ambient air for delivery to patients’ lungs through a ventilator, face mask or similar apparatus. Its approved product, LungFit® PH, is marketed in the United States for persistent pulmonary hypertension of the newborn and has European CE mark approval for specified infant and peri- and post-operative pulmonary hypertension uses. The company also develops LungFit® products for severe lung infections and nontuberculous mycobacteria lung infection. Beyond Air’s other programs include solid-tumor treatment using ultra-high concentrations of nitric oxide through its majority-owned affiliate Beyond Cancer, and neuronal nitric oxide synthase inhibitors for neurological conditions through its majority-owned affiliate NeuroNOS. It makes money through sales of its medical device products and is entitled to royalties from Beyond Cancer on future revenues and from a university agreement on net sales of nNOS inhibitors.

1
6
2

No SEC Form 4 filings for $XAIR in the last 30 days.

See all $XAIR insider activity →
Low

Beyond Air Reports Financial Results and Provides Corporate Update

Beyond Air, Inc. (XAIR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Beyond Air Reports Financial Results and Provides Corporate Update for the Quarter Ended September 30, 2026 Record quarterly revenue of $2.3 million, representing approximately 28% year-over-year growth, reflecting continued adoption of first-generation LungFit PH PM

Beyond Air 3Q 2026: Revenue $2.32M, EPS ($3.76) — 10-Q Summary

Beyond Air reported 3Q 2026 revenue of $2.32M, up 28% YoY, with a gross profit of $197K, reversing a prior-year loss. Net loss narrowed slightly. R&D expenses fell to $1.6M. LungFit GO received FDA Breakthrough Device Designation. The company expects to close the NeuroNOS divestiture in December 2026.

XAIR sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 9 news stories mentioning XAIR (Beyond Air, Inc.). Coverage has skewed bearish: 1 bullish, 6 neutral, and 2 bearish.

Recent XAIR coverage spans earnings, insider activity and financial news.

What's driving XAIR

AlphAI scores every news story that mentions XAIR with an AI model for sentiment and relevance, and aggregates insider trades from Beyond Air, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $XAIR

Score
$XAIRLowEarnings

Beyond Air Reports Financial Results and Provides Corporate Update

Beyond Air, Inc. (XAIR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Beyond Air Reports Financial Results and Provides Corporate Update for the Quarter Ended September 30, 2026 Record quarterly revenue of $2.3 million, representing approximately 28% year-over-year growth, reflecting continued adoption of first-generation LungFit PH PM

$XAIRMedEarnings

Beyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026

Beyond Air, Inc. (XAIR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Beyond Air ® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026 Preliminary revenue of $2.3 million represents the highest quarterly revenue reported, and approximately 30% sequential quarterly growth and 27% growth over the same period last ye

Beyond Air reports preliminary Q3 revenue of $2.3 million

Beyond Air Inc. (XAIR) reported preliminary Q3 2026 revenue of $2.3M, up 30% QoQ and 27% YoY, its highest quarterly revenue. The growth was driven by its LungFit PH system. The company reaffirmed its 2026 revenue guidance of $8M and 2027 guidance of $16M-$18M, pending FDA approval for its second-generation system. Final results are expected in November 2026.

Top insider buys and sells disclosed on Friday

Beyond Air (XAIR) director bought $56,590 in shares, Compass Therapeutics (CMPX) CFO acquired $18,400 in stock, Sky Harbour (SKYH) CFO purchased $15,040 in shares. CrowdStrike (CRWD) president sold $64M, Medpace (MEDP) CEO sold $30M, Snowflake (SNOW) director sold $17M. Insider trades may indicate confidence or tax obligations.

$XAIRLowExec change

Beyond Air, Inc. (XAIR): Entry into a Material Definitive Agreement

Beyond Air, Inc. (XAIR) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. The description in Item 5.02 below, as it relates to the terms and conditions of the Employment Agreement with Mr. Goodman, a copy of which is filed herewith as Exhibit 10.1, is incorporated herein by reference. Item 5.02. Dep

Related tickers